DK1523486T3 - Tetracykliske arylsulfonylindoler med serotoninreceptor-affinitet - Google Patents

Tetracykliske arylsulfonylindoler med serotoninreceptor-affinitet

Info

Publication number
DK1523486T3
DK1523486T3 DK03760857T DK03760857T DK1523486T3 DK 1523486 T3 DK1523486 T3 DK 1523486T3 DK 03760857 T DK03760857 T DK 03760857T DK 03760857 T DK03760857 T DK 03760857T DK 1523486 T3 DK1523486 T3 DK 1523486T3
Authority
DK
Denmark
Prior art keywords
pharmaceutically acceptable
compound
serotonin receptor
receptor affinity
indoles
Prior art date
Application number
DK03760857T
Other languages
English (en)
Inventor
Arava Veeraraeddy
Venkateswarlu Jasti
Venkata Satya Niro Ramakrishna
Rama Sastri Kambhampati
Srinivasa Reddy Battula
Venkata Satya Veerabhadra Rao
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Application granted granted Critical
Publication of DK1523486T3 publication Critical patent/DK1523486T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
DK03760857T 2002-06-21 2003-06-19 Tetracykliske arylsulfonylindoler med serotoninreceptor-affinitet DK1523486T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN478CH2002 2002-06-21
PCT/IN2003/000222 WO2004000849A2 (en) 2002-06-21 2003-06-19 Tetracyclic arylsulfonyl indoles having serotonin receptor affinity

Publications (1)

Publication Number Publication Date
DK1523486T3 true DK1523486T3 (da) 2008-03-03

Family

ID=29798513

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03760857T DK1523486T3 (da) 2002-06-21 2003-06-19 Tetracykliske arylsulfonylindoler med serotoninreceptor-affinitet

Country Status (16)

Country Link
US (1) US7649097B2 (da)
EP (1) EP1523486B1 (da)
JP (1) JP4473120B2 (da)
CN (1) CN100378108C (da)
AT (1) ATE377603T1 (da)
AU (1) AU2003249582B2 (da)
BR (1) BR0312176A (da)
CA (1) CA2490254C (da)
DE (1) DE60317333T2 (da)
DK (1) DK1523486T3 (da)
ES (1) ES2297216T3 (da)
MX (1) MXPA04012832A (da)
NZ (1) NZ537770A (da)
RU (1) RU2340619C2 (da)
WO (1) WO2004000849A2 (da)
ZA (1) ZA200409886B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005700A (es) * 2002-11-28 2005-08-16 Suven Life Sciences Ltd N-arilsulfonil-3-aminoalcoxiindoles.
EA009367B1 (ru) * 2002-12-18 2007-12-28 Сувен Лайф Сайенсиз Лимитед ПРОИЗВОДНЫЕ 5-ТИА-5-ДИОКСО-4b-АЗАИНДЕНО[2,1-a]ИНДЕНА, ОБЛАДАЮЩИЕ АФФИННОСТЬЮ К РЕЦЕПТОРУ СЕРОТОНИНА
AU2004312229B2 (en) * 2004-01-02 2010-05-20 Suven Life Sciences Limited Novel Indeno[2,1a]indenes and isoindolo[2,1-a]indoles
MXPA06011420A (es) * 2004-04-01 2007-04-20 Cardiome Pharma Corp Compuestos pegilados de modulacion de canal de iones.
SI1856132T1 (sl) * 2005-03-08 2009-08-31 Suven Life Sciences Ltd Postopek za pripravo substituiranih benzotiazinoindolov
CN119241381A (zh) 2019-12-26 2025-01-03 吉尔伽美什制药公司 芳基环己基胺衍生物及其在精神障碍的治疗中的用途
KR20260008838A (ko) 2020-02-18 2026-01-16 길가메쉬 파마슈티컬스, 인코포레이티드 기분 장애 치료에 사용되기 위한 특이적 트립타민
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
BR112022025306A2 (pt) 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
EP4396162A4 (en) 2021-09-03 2025-11-12 Alexander Shulgin Res Institute Inc ASYMMETRIC ALLYL TRYPTAMINES
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12180158B1 (en) 2023-08-03 2024-12-31 Gilgamesh Pharmaceuticals, Inc. Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amine

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489770A (en) * 1967-12-18 1970-01-13 American Home Prod 1-cyclo(lower)alkanoyl or admantanylcarbonyl - 3 - (2-substituted ethyl)indoles
ZA795239B (en) 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
GB8600397D0 (en) 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
CA2042295A1 (fr) 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
PT97888B (pt) 1990-06-07 1998-12-31 Zeneca Ltd Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
CZ283018B6 (cs) 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
GB9113802D0 (en) 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
US5206382A (en) * 1991-06-27 1993-04-27 Fidia Georgetown Institute For The Neurosciences Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders
FR2686878B1 (fr) * 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
GB9210400D0 (en) 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
KR940007001A (ko) 1992-09-16 1994-04-26 최승주 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제
KR20010032668A (ko) * 1997-12-03 2001-04-25 우에하라 아끼라 함질소 사환성 화합물
JP2000026471A (ja) 1998-07-10 2000-01-25 Nippon Soda Co Ltd 11−ホルミル−インドロ[1,2−b][1,2]ベンズイソチアゾールおよび農園芸用殺菌剤
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
CA2353962C (en) 1998-12-11 2009-09-29 Virginia Commonwealth University Selective 5-ht6 receptor ligands
DK1859798T3 (da) 2001-03-29 2016-03-21 Lilly Co Eli N-(2-arylethyl) -benzylaminer som antagonister af 5-ht6-receptoren

Also Published As

Publication number Publication date
JP4473120B2 (ja) 2010-06-02
NZ537770A (en) 2007-03-30
RU2005101344A (ru) 2005-08-20
CN1662544A (zh) 2005-08-31
ATE377603T1 (de) 2007-11-15
DE60317333D1 (de) 2007-12-20
CA2490254C (en) 2011-11-01
EP1523486B1 (en) 2007-11-07
RU2340619C2 (ru) 2008-12-10
US7649097B2 (en) 2010-01-19
WO2004000849A3 (en) 2004-03-25
EP1523486A2 (en) 2005-04-20
ZA200409886B (en) 2006-07-26
US20050203154A1 (en) 2005-09-15
CN100378108C (zh) 2008-04-02
BR0312176A (pt) 2005-04-05
JP2005535621A (ja) 2005-11-24
ES2297216T3 (es) 2008-05-01
HK1074843A1 (en) 2005-11-25
MXPA04012832A (es) 2005-05-27
AU2003249582B2 (en) 2006-08-03
DE60317333T2 (de) 2008-08-28
WO2004000849A2 (en) 2003-12-31
CA2490254A1 (en) 2003-12-31
AU2003249582A1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
WO2004048330A8 (en) N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
DK1523486T3 (da) Tetracykliske arylsulfonylindoler med serotoninreceptor-affinitet
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
CY1111876T1 (el) Νεες πυρρολες με υπολiπiδaiμiκες και υποχοληστερολαιμικες δραστικοτητες, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που τις περιεχουν και η χρηση αυτων στην ιατρικη
MY141559A (en) Triazole derivatives as tachykinin receptor antagonists
BG107171A (bg) Производни на пурин
EA200400762A1 (ru) Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции
DE602004005960D1 (de) Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
MXPA03000161A (es) Compuestos novedosos los cuales tienen actividad antiinflamatoria, proceso para su preparacion y composiciones farmaceuticas que las contienen.
YU75101A (sh) Supstituisani biciklični heterocikli, postupak njihove izrade i njihova upotreba kao antigojaznih i hipoholesterolemijskih agenasa
DK1537113T3 (da) Arylalkylindoler med serotoninreceptoraffinitet anvendelige som terapeutiske midler, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
ATE505462T1 (de) Neue biologischaktive molekü le
WO2004055026A8 (en) Tetracyclic 3-substituted indoles having serotonin receptor affinity
ZA200409887B (en) Novel tetracyclic arylcarbonyl Indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
PT1673354E (pt) Arilindenopiridinas e arilindenopirimidinas e sua utilização como antagonistas do receptor da adenosina a2a
UA88910C2 (ru) Гетероциклические соединения для предотвращения или ослабления симптомов заболеваний, которые лечатся коноплей, и способы их получения
TW200634008A (en) Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition